NEW YORK, May 18 (GenomeWeb News) - Genomatix, a Roanoke, Va.-based gene expression and proteomics tools company, today announced that it has closed a Series B round of financing led by a $500,000 investment from NewVa Capital Partners, a venture capital fund managed by Third Security.
Robert Beech, CEO of Genomatix, said in a statement that the new funding will "accelerate the roll out and marketing of its proprietary genetic tools," and called NewVa's investment a "strong indicator" that the company was on the "right track, both scientifically and commercially."